Bristol-Myers Squibb Company
TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE
Last updated:
Abstract:
The present invention provides compounds of Formula (I). wherein A and Z are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and may be useful for the treatment and/or prophylaxis of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases. ##STR00001##
Status:
Application
Type:
Utility
Filling date:
10 Mar 2017
Issue date:
17 Sep 2020